Literature DB >> 1407392

Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.

J Adrien1, M H Tissier, L Lanfumey, S Haj-Dahmane, T Jolas, B Franc, M Hamon.   

Abstract

Anxiolytic drugs, such as the benzodiazepines and the azapirones (ipsapirone, gepirone, buspirone), are well known to affect states of vigilance and to decrease the firing rate of serotoninergic neurones within the dorsal raphe nucleus in rats. In order to examine whether the newly developed 5-HT3 antagonists with potential anxiolytic properties act through similar mechanisms, the effects of several of such antagonists: MDL 72222, ICS 205-930, ondansetron and/or zacopride on both sleep-wakefulness and the discharge of serotoninergic neurones within the dorsal raphe nucleus were investigated in rats. When tested in a wide range of doses (0.05-10 mg/kg, i.p.), none of these drugs significantly affected the states of vigilance, except ondansetron, at 0.1 mg/kg, which increased paradoxical sleep for the first 2 hr after administration and MDL 72222, at 10 mg/kg, which reduced both paradoxical and slow wave sleep and increased wakefulness for the same initial period after treatment. In vivo, in chloral hydrate anaesthetized rats, as well as in vitro, in slices of brain stem, none of the 5-HT3 antagonists tested affected the firing rate of serotoninergic neurones. Similarly, no change in the electrical activity of serotoninergic neurones could be evoked in vitro by superfusion of the tissue with the 5-HT3 agonists, phenylbiguanide (10 microM) and 2-methyl-5-HT (1 microM). At a larger concentration (10 microM), the latter compound reduced the neuronal discharge probably through the stimulation of somatodendritic 5-HT1A autoreceptors since this effect, as that of ipsapirone, could be prevented by 10 microM l-propranolol. Comparison of these data with those obtained with benzodiazepines and 5-HT1A agonists of the azapirone series, supports the concept that different mechanisms are responsible for the anxiolytic-like properties of 5-HT3 agonists, compared to those of other anxiolytic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1407392     DOI: 10.1016/0028-3908(92)90183-p

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

Review 1.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Response of Htr3a knockout mice to antidepressant treatment and chronic stress.

Authors:  Vincent Martin; Armance Riffaud; Tevrasamy Marday; Charly Brouillard; Bernard Franc; Jean-Pol Tassin; Caroline Sevoz-Couche; Raymond Mongeau; Laurence Lanfumey
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

Review 3.  Modulating role of serotonergic signaling in sleep and memory.

Authors:  Salar Vaseghi; Shirin Arjmandi-Rad; Maliheh Eskandari; Mahshid Ebrahimnejad; Gita Kholghi; Mohammad-Reza Zarrindast
Journal:  Pharmacol Rep       Date:  2021-11-06       Impact factor: 3.024

4.  Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Caterina Scuderi; Baoman Li
Journal:  Adv Neurobiol       Date:  2021

5.  Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.

Authors:  J C Gillin; W Jernajczyk; D C Valladares-Neto; S Golshan; M Lardon; S M Stahl
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

6.  Temperature, food intake, and locomotor activity effects of a 5-HT3 receptor agonist and two 5-HT3 receptor antagonists in rats.

Authors:  P Mazzola-Pomietto; C S Aulakh; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

8.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.

Authors:  Sue Wilson; Astrid-Maria Højer; Jeppe Buchberg; Johan Areberg; David J Nutt
Journal:  J Psychopharmacol       Date:  2015-08-07       Impact factor: 4.153

9.  Analysis of sleep disorders under pain using an optogenetic tool: possible involvement of the activation of dorsal raphe nucleus-serotonergic neurons.

Authors:  Hisakatsu Ito; Makoto Yanase; Akira Yamashita; Chigusa Kitabatake; Asami Hamada; Yuki Suhara; Michiko Narita; Daigo Ikegami; Hiroyasu Sakai; Mitsuaki Yamazaki; Minoru Narita
Journal:  Mol Brain       Date:  2013-12-26       Impact factor: 4.041

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.